Table 1 Safety of commonly used anti-COVID-19 drugs
From: The prevention and treatment of COVID-19 in patients treated with hemodialysis
Medicines | Cases (n) | AE (%) | SAE (%) | Common AE | Identifier |
|---|---|---|---|---|---|
Convalescent plasma | 468 | NA | NA | Bleeding, Venous thromboembolism, Arterial thromboembolism | NCT04364737 [35] |
Intravenous immunoglobulin | 68 | 75.0% | 32.0% | Abdominal or back pain, fever, headache, chills, rash, fatigue, nausea or vomiting | NCT04350580 [42] |
REGN-COV2 | 3688 | 7.1–8.4% | 1.1–1.7% | Infusion-related reactions and hypersensitivity reactions | NCT04425629 [46] |
LY-CoV555 + LY-CoV016 | 518 | 13.3% | 1.4% | Nausea, rash, dizziness, diarrhea and hypertension | NCT04427501 [47] |
AZD7442 | 3461 | 35.3% | 1.4% | Injection site reactions | NCT04625725 [48] |
Paxlovid | 1109 | 22.6% | 1.6% | Dysphagia, diarrhea and vomiting | NCT04960202 [50] |
Molnupiravir | 710 | 30.4% | 6.9% | Diarrhea, malignancy and dizziness | NCT04575597 [54] |
VV116 | 384 | 67.4% | 0.3% | Dysgeusia, hypertriglyceridemia and hyperlipidemia | NCT05341609 [58] |
Azvudine | 10 | 0.0% | 0.0% | NA | ChiCTR2000029853 [60] |
Metformin | 663 | NA | NA | Rhinorrhea, cough, fatigue, myalgia and headache | NCT04510194 [68] |